Company intelligence / Profile preview

TriSalus Life Sciences

Denver, Colorado, United Statestrisaluslifesci.com ↗

Ownership: Public · TLSI
Employees: ~199
Development stage: Commercial

Overview

TriSalus has two FDA-cleared devices using proprietary Pressure-Enabled Drug Delivery technology. The company is also developing nelitolimod (SD-101), an investigational TLR9 agonist immunotherapy, with Phase 1 clinical trials completed and Phase 2 trials in progress for various cancer indications.

Therapeutic areas: Oncology
Modalities: ImmunotherapyDrug Delivery Technology
Industry: Biotech

Drug pipeline

2 assets

nelitolimod

1 more asset in the full pipeline.

Request access →

Partnerships

MD Anderson Cancer Center

Financials

Market cap: $293.1M
Total revenue: $11.4M
Enterprise value: $281.2M

Beyond the preview

Go deeper on TriSalus Life Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TriSalus Life Sciences.

Explore the full profile